Market News & Trends
Halberd Corp. Discovers a Proprietary Disease-Causing Antigen Removal Process Method Does Not Require Antibody Conjugated Metallic Nanoparticles
Halberd Corporation recently announced a possible breakthrough method for the removal of the disease-causing antigen(s) that does not require the use of metallic nanoparticles conjugated…
OSE Immunotherapeutics Announces Manufacturing Agreement With Cenexi
OSE Immunotherapeutics and Cenexi recently announced the signature of an agreement whereby Cenexi will manufacture clinical batches of CoVepiT, OSE Immunotherapeutics' vaccine candidate against COVID-19 currently…
Altimmune Announces Update on AdCOVID Phase 1 Clinical Trial
Altimmune, Inc. recently provided an update on its AdCOVID investigational vaccine for the prevention of COVID-19. The company also provided an update on its T-COVID…
Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes
Adocia recently announced the launch of a Phase 1 clinical study in collaboration with Dr. Ahmad Haidar, McGill University, Canada, to assess pharmacokinetic, glycemic control…
Avacta Announces AffiDX SARS-CoV-2 Antigen Lateral Flow Test Detects Delta Variant
Avacta Group plc recently announced that a study has shown that the AffiDX antigen lateral flow test detects the Delta variant of the SARS-CoV-2 virus…
CN Bio’s PhysioMimix Adopted by King’s College London to Investigate Chronic Liver Disease
CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single and multi-organ microphysiological systems (MPS), recently announced that King’s College London, an internationally…
Orchard Therapeutics Announces Regulatory & Clinical Updates for Lead Gene Therapy Programs
Orchard Therapeutics recently announced several program updates for the company’s portfolio of approved and investigational hematopoietic stem cell (HSC) gene therapies. These updates follow recent…
CicloMed Announces Initiation of Phase 1B Trial of Fosciclopirox in Newly Diagnosed & Recurrent Urothelial Cancer Patients
CicloMed LLC recently announced that the Phase 1B clinical trial of fosciclopirox for the treatment of bladder cancer is now open. “We are excited to…
Addex Therapeutics Initiates Pivotal Phase 2b/3 Study With Dipraglurant for Dyskinesia Associated With Parkinson’s Disease
Addex Therapeutics Ltd recently announced that screening of patients has started for its pivotal Phase 2b/3 study with dipraglurant for dyskinesia associated with Parkinson’s disease…
Veru Announces the Presentation of a Phase 1b/2 Clinical Study Update for Sabizabulin
Veru Inc. recently announced updated clinical results from the ongoing Phase 1b/2 clinical study of sabizabulin (VERU-111), an oral cytoskeleton disruptor being evaluated for the…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….